Global Blood Therapeutics IPO

8/12/2015

IPO

$120,000,000

We intend to use the net proceeds from this offering and our cash and cash equivalents on hand as follows: approximately $50.0 million to fund our development of GBT440 for the treatment of SCD, including the completion of our ongoing Phase 1/2 clinical trial, planned clinical pharmacology studies and through the initiation of a pivotal clinical trial; approximately $15.0 million to conduct clinical trials of GBT440 or its analogs for the treatment of hypoxemic pulmonary disorders; approximately $15.0 million to complete and file an IND and begin a Phase 1/2 clinical trial of an oral kallikrein inhibitor for the treatment of HAE; and the remaining proceeds, if any, to fund new and ongoing research and development activities, working capital and other general corporate purposes, which may include funding for the hiring of additional personnel, capital expenditures and the costs of operating as a public company. Based on our current plans, we believe our cash and cash equivalents, togeth

Publicly-held

Biopharmaceutical

171 Oyster Point Blvd. 300
San Francisco, CA 94080
USA

Global Blood Therapeutics develops oral medicines for the treatment of chronic blood-based diseases and severe genetic disorders.